What we are looking for: The REPAIR Impact Fund invests in start-ups, early-stage companies and corporate spin-outs in Europe and the United States. Our philosophy is to support ambitious programmes addressing antibiotic resistance through a broad range of therapeutic modalities.
At Novo Holdings, we believe that innovation is the key to longer-term success. We will therefore give priority to first-in-class therapies, covering small molecules, biologics and new modalities, from the early stage of drug development (lead optimization) to the early stages of clinical development (Phase 1). We are equally comfortable investing as the sole investor or in a syndicate, with convertible loans or royalty-based instruments ranging from USD 1 million to USD 15 million.
SEE LIST OF THE MOST URGENT MULTI-DRUG RESISTANT INFECTIONS
Main CriteriaThe first-pass selection priorities will be based on a non-confidential presentation. Companies given priority will then be invited to send a full business plan with an extended presentation of the scientific rationale, available data, budget and development plan, including milestones, to be reviewed by our Scientific Selection Board. Based on the assessment of the Scientific Selection Board, including a question-and-answer process, the finalists will be nominated and invited to present their projects live to the Scientific Selection Board at a meeting in Europe or the United States.
· Pathogens: from the high-priority list of the World Health Organization and the United States Centers for Disease Control and Prevention
· Therapies: first-in-class therapies have priority
· Modalities: small molecules, biologics and new modalities
· Phases: from the early stage of drug development (lead optimization) to the early stages of clinical development (Phase 1)